Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

The new diagnostic, part of Roche’s Ventana platform, has been approved in the US under the Pathway brand since October 2022. In Europe, it is called the Ventana HER2 (4B5) test – already used ...

ANGLE has also successfully completed its contract with the global pharmaceutical company, Eisai Inc. ("Eisai") demonstrating the ability to measure HER2 CTC ... the assays to test blood samples ...

However, doctors differ in their views on testing before prescribing ... Slamon points out that the two pathways are linked. When HER2 is amplified, “one of the pathways that consistently ...

Although Eisai decided not to option a HER2-targeted drug under a deal with BlissBio, Angle wants to keep working with the firms to advance its CTC technology.